Latest news with #GlaukosCorporation
Business Wire
6 days ago
- Business
- Business Wire
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at About Glaukos Glaukos ( is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose ® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Yahoo
12-05-2025
- Business
- Yahoo
Glaukos Corporation (GKOS) Fell as its iDose Results Fell Short of Expectations
Baron Funds, an investment management company, released its 'Baron Health Care Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Glaukos Corporation (NYSE:GKOS). Glaukos Corporation (NYSE:GKOS) is an ophthalmic pharmaceutical and medical technology company. The one-month return of Glaukos Corporation (NYSE:GKOS) was -3.18%, and its shares lost 16.98% of their value over the last 52 weeks. On May 9, 2025, Glaukos Corporation (NYSE:GKOS) stock closed at $89.96 per share with a market capitalization of $5.14 billion. Baron Health Care Fund stated the following regarding Glaukos Corporation (NYSE:GKOS) in its Q1 2025 investor letter: "Glaukos Corporation (NYSE:GKOS) develops and sells interventional glaucoma treatments, including iDose, a minimally invasive drug-delivery device launched in 2024. An iDose is implanted as a five minute procedure and delivers highly concentrated prostaglandin inside the eye effective for up to three years. Shares declined on quarterly iDose results that missed elevated investor expectations. Although feedback has been positive, doctors have been hesitant to use iDose until they are confident they will receive reimbursement for this expensive device. Medicare coverage has started to solidify in some regions, and we think coverage across the board is a matter of when, not if. We believe uptake will accelerate over the coming quarters as the reimbursement process becomes more streamlined. Glaucoma is a large market that is ripe for new standalone interventions, and we think iDose can be a $1 billion product over time." A doctor examining a patient's eyes with an ophthalmic medical device. Glaukos Corporation (NYSE:GKOS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held Glaukos Corporation (NYSE:GKOS) at the end of the fourth quarter compared to 32 in the third quarter. In the first quarter of 2025, Glaukos Corporation's (NYSE:GKOS) reported revenue of $106.7 million representing 25% increase on a reported basis, or 26% on a constant currency basis compared to Q1 2024. While we acknowledge the potential of Glaukos Corporation (NYSE:GKOS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Glaukos Corporation (NYSE:GKOS) and shared ClearBridge Small Cap Growth Strategy's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
08-04-2025
- Business
- Yahoo
What Makes Glaukos Corporation (GKOS) a Compelling Stock?
ClearBridge Investments, an investment management company, released its 'ClearBridge Small Cap Growth Strategy' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market performance in the first quarter of 2025 was volatile, following the initial 'animal spirits' post-election rally. The strategy surpassed its benchmark with the support of new ideas, reorienting efforts, and tailwinds in several industries despite volatility and uncertainty. Given the pace of major policy changes, the firm expects ongoing volatility as the effects of tariffs and policymaking have clouded visibility. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first quarter 2025 investor letter, ClearBridge Small Cap Growth Strategy emphasized stocks such as Glaukos Corporation (NYSE:GKOS). Glaukos Corporation (NYSE:GKOS) is an ophthalmic pharmaceutical and medical technology company. The one-month return of Glaukos Corporation (NYSE:GKOS) was -11.98%, and its shares lost 15.04% of their value over the last 52 weeks. On April 7, 2025, Glaukos Corporation (NYSE:GKOS) stock closed at $86.07 per share with a market capitalization of $4.869 billion. ClearBridge Small Cap Growth Strategy stated the following regarding Glaukos Corporation (NYSE:GKOS) in its Q1 2025 investor letter: "We continued to generate a number of compelling new ideas, adding five new investments that we still held at quarter end: Glaukos Corporation (NYSE:GKOS), Rocket Lab USA, Karman Holdings (through its IPO), Archrock, Hims & Hers and Geron. A doctor examining a patient's eyes with an ophthalmic medical device. Glaukos Corporation (NYSE:GKOS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held Glaukos Corporation (NYSE:GKOS) at the end of the fourth quarter compared to 32 in the third quarter. In 2024, Glaukos Corporation's (NYSE:GKOS) consolidated net sales grew 22% year over year to $383.5 million. While we acknowledge the potential of Glaukos Corporation (NYSE:GKOS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. We covered Glaukos Corporation (NYSE:GKOS) in another article, where we shared the list of best medical technology stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
